Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

JW Therapeutics Releases Positive Data from CAR-T Trial for Lymphoma

publication date: Dec 9, 2020

JW Therapeutics of Shanghai presented positive data from its leading CAR-T therapy for patients with B-cell lymphoma. In a pivotal trial, relmacabtagene autoleucel (relma-cel) produced efficacy similar to already-approved CAR-T treatments, but with a better side effect profile. JW has filed for approval of the anti-CD19 CAR-T candidate in China and expects it will be the first CAR-T approved as a Class 1 drug. JW is a joint venture formed by Juno Therapeutics of Seattle and Shanghai's WuXi Biologics. More details....

Stock Symbol: (HK: 2126)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.